Search

Meet the Stuart family and learn why they want to revolutionize cancer treatment for people ages 15 to 39 and meet their very specific and often unmet needs.

… Friday, October 1, 2021 VIDEO | 03:15 A Gift for Life Meet the Stuart family and learn about their transformational gift to launch the Lisa and Scott Stuart Center for Adolescent and Young Adult Cancers at MSK. Video Details If you ask Scott Stuart, he will tell you that Memorial Sloan Kettering Cancer

Two second-year students -- Ellen Hukkelhoven and John Halliday -- were named Grayer Fellows for the 2010-2011 year.

… Saturday, May 1, 2010 Two second-year students were named Grayer Fellows for the 2010-2011 year. They are Ellen Hukkelhoven and John Halliday. These fellowships were established by Mr. and Mrs. Jonathan Grayer. Mr. Grayer is a member of the Gerstner Sloan Kettering Board of Trustees and the former chairman

An inherited mutation that contributes to lung cancer spread could be a target for therapies.

… Thursday, November 3, 2022 An inherited mutation in a gene called BRMS1 promotes lung cancer lung cancer metastasis.   The mutation could be targeted with therapies that prevent metastasis. Lung cancer is the leading cause of cancer death in the United States. The primary reason the disease is so deadly

Maria Jasin, PhD, a molecular biologist at the Sloan Kettering Institute, was named a recipient of the Shaw Prize in Life Science and Medicine. Dr. Jasin was recognized for her contributions to research showing that localized double-strand breaks in DNA stimulate recombination in mammalian cells.

… Tuesday, May 21, 2019 Maria Jasin, PhD , a molecular biologist at the Sloan Kettering Institute , was named a recipient of the Shaw Prize in Life Science and Medicine . Dr. Jasin was recognized for her contributions to research showing that localized double-strand breaks in DNA stimulate recombination

MSK physicians and scientists highlighted some of the institution’s latest advances in transplantation and cellular therapies at the Tandem Meetings held February 4 to 6, 2026, in Salt Lake City.

… Monday, April 6, 2026 Memorial Sloan Kettering Cancer Center (MSK) physicians and scientists highlighted some of the institution’s latest advances in transplantation and cellular therapies at the  Tandem Meetings held February 4 to 6, 2026, in Salt Lake City. The meetings, jointly hosted by the American

Memorial Sloan Kettering Cancer Center (MSK) announces its most recent awards and appointments for the institution’s physicians, scientists, nurses, and staff.

… Tuesday, August 17, 2021 Memorial Sloan Kettering Cancer Center (MSK) announces the following awards and appointments: Craig Thompson Recognized in City & State’s Life Sciences Power 50 Craig B. Thompson Craig Thompson, MD , President and CEO, was named on the inaugural City & State Life Sciences Power

The Starr Foundation today announced that it has made a $100 million grant to create a wide-ranging cancer consortium to coordinate the efforts of five internationally renowned research institutions in the fight against cancer. Joining this ambitious undertaking are The Broad Institute of MIT and Harvard, Cold Spring Harbor Laboratory, Memorial Sloan Kettering Cancer Center, The Rockefeller University and Weill Cornell Medical College.

… Thursday, September 21, 2006 The Starr Foundation today announced that it has made a $100 million grant to create a wide-ranging cancer consortium to coordinate the efforts of five internationally renowned research institutions in the fight against cancer. Joining this ambitious undertaking are The Broad

Neratinib, which targets mutations that drive cancer growth, is showing promise for treating several types of cancer.

… Sunday, April 2, 2017 Summary Neratinib,  an experimental drug developed to target certain mutations that drive cancer growth, is showing promise for treating several types of cancer. The findings from a phase II study were presented at the 2017 AACR Annual Meeting . Highlights Basket trials are based

New findings could lead to a different kind of cancer drug that targets a DNA damage repair pathway called nucleotide excision repair.

… Monday, January 11, 2021 Summary A study has uncovered new findings about a DNA repair pathway called nucleotide excision repair and its role in the development of cancer. The paper also details how this defective pathway could be targeted with drugs. Memorial Sloan Kettering scientists have discovered

Learn more about DeepHeme, an artificial intelligence tool that helps doctors to diagnose blood and bone marrow cancers.

… Wednesday, June 11, 2025 Researchers at Memorial Sloan Kettering Cancer Center (MSK), the University of California, San Francisco (UCSF), and University of California, Berkeley (UC Berkeley) have developed an artificial intelligence (AI) tool called DeepHeme that can help automate the diagnosis of blood